Zolendronate in osteogenesis imperfecta.
Inusha
I
Panigrahi
Rashmi Ranjan
RR
Das
Ram Kumar
RK
Marwaha
D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D005598:Fractures, Spontaneous / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007223:Infant; D007231:Infant, Newborn; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism; D008297:Male; D010013:Osteogenesis Imperfecta / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D011859:Radiography; D012189:Retrospective Studies; D016896:Treatment Outcome; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid